Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TERN - Terns Pharmaceuticals Inc


IEX Last Trade
7.62
-0.060   -0.787%

Share volume: 627,819
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$7.68
-0.06
-0.78%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-7.30%
1 Month
-0.65%
3 Months
8.55%
6 Months
1.74%
1 Year
39.05%
2 Year
93.40%
Key data
Stock price
$7.62
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$3.26 - $10.03
52 WEEK CHANGE
$0.42
MARKET CAP 
492.840 M
YIELD 
N/A
SHARES OUTSTANDING 
64.677 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
1.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$842,533
AVERAGE 30 VOLUME 
$992,572
Company detail
CEO:
Region: US
Website: ternspharma.com
Employees: 44
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.

Recent news